Axsome Therapeutics
AXSM
AXSM
230 hedge funds and large institutions have $2.61B invested in Axsome Therapeutics in 2023 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 89 increasing their positions, 54 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
17% more funds holding
Funds holding: 196 → 230 (+34)
4.83% more ownership
Funds ownership: 73.3% → 78.13% (+4.8%)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Holders
230
Holding in Top 10
8
Calls
$106M
Puts
$60.5M
Top Buyers
| 1 | +$71.9M | |
| 2 | +$54.9M | |
| 3 | +$36.2M | |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$33.1M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$27.6M |
Top Sellers
| 1 | -$50.4M | |
| 2 | -$43.5M | |
| 3 | -$32.6M | |
| 4 |
Millennium Management
New York
|
-$21.9M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$9.41M |